Zofia E. Dziewanowska

Author

Also Known As

Z Dziewanowska, Z. Dziewanowska, Z. E. Dziewanowska, Z.E. Dziewanowska, Zofia Dziewanowska, Zofia Dziewanowska, MD, PhD, Zofia E Dziewanowska, Zofia E. Dziewanowska

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Ligand Pharmaceuticals (United States)La Roche College Los Angeles Clinical Trials

About

Zofia E. Dziewanowska is an author at Ligand Pharmaceuticals (United States) specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1.1K
2	Immunology	5	5	934
3	Health Sciences	3	3	66
4	Biochemistry	1	1	22
5	Endocrinology	1	1	114

Zofia E. Dziewanowska

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
BCL-2 antisense therapy in patients with non-Hodgkin lymphoma Andrew Webb, David Cunningham, Finbarr E. Cotter, The Lancet Bcl-2 Antisense TherapyLymphoid NeoplasiaMedicineImmunologyAdult T-cell Leukemia-lymphoma	1997	498
First demonstration of anti-lymphoma activity of BCL-2 antisense molecule-G3139; Results of phase I/IIA clinical trial Amy Webb, David Cunningham, Finbarr E. Cotter, European Journal of Cancer Hematological MalignancyLymphoid NeoplasiaMedicineAnti-lymphoma ActivityImmunology	1997	320
Circadian changes in the bioavailability and effects of indomethacin in healthy subjects J. Clench, Alain Reinberg, Zofia E. Dziewanowska, European Journal of Clinical Pharmacology SleepAlertnessHealthy SubjectsMedicinePhysiology	1981	114
Phase III Trial Comparing Carboplatin, Paclitaxel, and Bexarotene With Carboplatin and Paclitaxel in Chemotherapy-Naïve Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: SPIRIT II George R. Blumenschein, Fadlo R. Khuri, Joachim von Pawel, Journal of Clinical Oncology	2008	96
Randomized Phase III Trial Comparing Bexarotene (L1069-49)/Cisplatin/Vinorelbine With Cisplatin/Vinorelbine in Chemotherapy-Naïve Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: SPIRIT I Rodryg Ramlau, Petr Zatloukal, Jacek Jassem, Journal of Clinical Oncology	2008	90
Interferon-??2a in the Treatment of Acquired Immunodeficiency Syndrome-Related Kaposi??s Sarcoma Lydia M. Evans, Loretta M. Itri, Marilyn Campion, Journal of Immunotherapy ImmunodeficienciesImmunologyPathologyPharmacotherapyAntiviral Drug	1991	70
Sleep improves when patients with chronic OA pain are managed with morning dosing of once a day extended-release morphine sulfate (AVINZA®): Findings from a pilot study Murray Rosenthal, Polly Moore, Eric S. Groves, Journal of Opioid Management	2007	45
A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC) G. R. Blumenschein, Fadlo R. Khuri, U. Gatzemeier, Journal of Clinical Oncology Surgical OncologyChemoprevention StrategyCancer ManagementPharmacotherapyMetronomic Chemotherapy	2005	30
Intravenous and intramuscular pharmacokinetics of recombinant leukocyte a interferon Larisa D. Bornemann, H.E. Spiegel, Zofia E. Dziewanowska, European Journal of Clinical Pharmacology Intramuscular PharmacokineticsGranulocyteImmunologyHematologyTherapeutic Efficacy	1985	27
Identification of polymorphisms associated with hypertriglyceridemia and prolonged survival induced by bexarotene in treating non-small cell lung cancer. Wen Luo, Nicholas J. Schork, Keith B. Marschke, PubMed	2011	25

Page 1